Liver Cirrhosis

Gastroenterology
4
Pipeline Programs
14
Companies
15
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 14 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
1 program
1
peginterferon alfa-2a 180μgPhase 31 trial
Active Trials
NCT00304551Completed180Est. Jun 2010
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
4 programs
2
BI 3802876Phase 21 trial
BILN 2061 ZWPhase 21 trial
CaffeineN/A1 trial
RosuvastatinN/ASmall Molecule1 trial
Active Trials
NCT05741385Completed4Est. Aug 2024
NCT05741372Completed28Est. Dec 2024
NCT07325526Recruiting30Est. Mar 2027
+1 more trials
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
SHED groupPhase 11 trial
Active Trials
NCT03957655UnknownEst. Dec 2021
Genomics
GenomicsUK - Oxford
2 programs
Multi-analyte Blood TestN/A1 trial
Multi-analyte blood TestN/A1 trial
Active Trials
NCT05199259Recruiting1,200Est. Mar 2025
NCT03694600Unknown1,900Est. Jun 2024
Bayer
BayerLEVERKUSEN, Germany
1 program
Abdominal USN/A1 trial
Active Trials
NCT06312826Active Not Recruiting806Est. Dec 2027
Olympus
OlympusPA - Center Valley
1 program
ElastographyN/A1 trial
Active Trials
NCT04533932Unknown40Est. Aug 2021
AB
AP BiosciencesTaiwan - Taipei
1 program
Nutritional Assessment in Individuals with Liver CirrhosisN/A1 trial
Active Trials
NCT06588712Not Yet RecruitingEst. Apr 2029
Roche
RocheSTAVANGER NORWAY, Norway
1 program
PIVKA-II and GAAD score calculationN/A1 trial
Active Trials
NCT07298577Not Yet Recruiting2,100Est. Jun 2030
Grifols
GrifolsNEW YORK, NY
1 program
Plasma exchange with albuminN/A1 trial
Active Trials
NCT01201720CompletedEst. Feb 2013
Ambrosia Biosciences
1 program
Probiotics-Bio-plusN/A1 trial
Active Trials
NCT00312910CompletedEst. Oct 2007
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
RifaximinN/A1 trial
Active Trials
NCT01951209TerminatedEst. Jun 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chugai Pharmapeginterferon alfa-2a 180μg
Boehringer IngelheimBI 3802876
Boehringer IngelheimBILN 2061 ZW
T-TherapeuticsSHED group
RochePIVKA-II and GAAD score calculation
AP BiosciencesNutritional Assessment in Individuals with Liver Cirrhosis
Boehringer IngelheimCaffeine
Boehringer IngelheimRosuvastatin
BayerAbdominal US
GenomicsMulti-analyte Blood Test
OlympusElastography
GenomicsMulti-analyte blood Test
Bausch HealthRifaximin
GrifolsPlasma exchange with albumin
Ambrosia BiosciencesProbiotics-Bio-plus

Clinical Trials (15)

Total enrollment: 6,298 patients across 15 trials

NCT00304551Chugai Pharmapeginterferon alfa-2a 180μg

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Start: Jun 2006Est. completion: Jun 2010180 patients
Phase 3Completed

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Start: Feb 2026Est. completion: Mar 202730 patients
Phase 2Recruiting

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C

Start: Sep 200210 patients
Phase 2Completed

Safety and Efficacy of SHED for Decompensated Liver Cirrhosis

Start: Dec 2019Est. completion: Dec 2021
Phase 1Unknown
NCT07298577RochePIVKA-II and GAAD score calculation

Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

Start: Jan 2026Est. completion: Jun 20302,100 patients
N/ANot Yet Recruiting
NCT06588712AP BiosciencesNutritional Assessment in Individuals with Liver Cirrhosis

Nutritional Assessment in Individuals with Liver Cirrhosis

Start: Oct 2024Est. completion: Apr 2029
N/ANot Yet Recruiting

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Start: Oct 2023Est. completion: Aug 20244 patients
N/ACompleted

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Start: Sep 2023Est. completion: Dec 202428 patients
N/ACompleted
NCT06312826BayerAbdominal US

Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk

Start: Aug 2022Est. completion: Dec 2027806 patients
N/AActive Not Recruiting
NCT05199259GenomicsMulti-analyte Blood Test

Multi-analyte Blood Test Clinical Trial

Start: Mar 2022Est. completion: Mar 20251,200 patients
N/ARecruiting
NCT04533932OlympusElastography

Endosonographic Shear Wave Elastography for Liver Stiffness

Start: Sep 2020Est. completion: Aug 202140 patients
N/AUnknown
NCT03694600GenomicsMulti-analyte blood Test

Clinical Trial Multi-analyte Blood Test

Start: Feb 2019Est. completion: Jun 20241,900 patients
N/AUnknown

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Start: Nov 2016Est. completion: Jun 2017
N/ATerminated
NCT01201720GrifolsPlasma exchange with albumin

Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"

Start: Mar 2011Est. completion: Feb 2013
N/ACompleted

Probiotics for the Prevention of Major Complications of Cirrhosis

Start: Apr 2005Est. completion: Oct 2007
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 6,298 patients
14 companies competing in this space